Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Ascletis and Roche to Develop Hepatitis C Treatment for China

publication date: Apr 15, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Ascletis, a two-year-old China pharma startup, will collaborate with Roche to develop a Roche drug candidate for treatment of hepatitis C virus in China. Danoprevir is a protease inhibitor that has shown efficacy in European Phase II tests against HCV genotypes 1b and 4. Aslectis’ first deal was also a liver drug: an RNAi based treatment for liver cancer developed by Alnylam Pharma. More details....

Stock Symbols: (VX: ROG) (NSDQ: ALNY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners